Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
Primary Purpose
Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring
Status
Recruiting
Phase
Phase 3
Locations
Qatar
Study Type
Interventional
Intervention
Dexamethasone Oral
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Urinary Tract Infections in Children
Eligibility Criteria
Inclusion Criteria:
- First episode of acute febrile UTI.
- From 2 months to 14 years of age.
- Fever: ≥ 38.3°C, measured at home or at Pediatric Emergency centers.,
Exclusion Criteria:
- Previous history of UTI.
- Urinary tract abnormalities except VUR.
- Antibiotic use within 7 days of enrollment (except last 48 hours)
- previous renal scarring
- patients included in the study and suffered second pyelonephritis during the first 6 months
- Patients allergic to dexamethasone.
- Endocrinology diseases.
- cancer.
- Planned admission to ICU
- Other bacterial infection as meningitis or pneumonia
- Congenital/acquired immunodeficiency
- Systemic use of corticosteroids or other immunomodulation agents within 14 days of enrollment.
Sites / Locations
- Hamad Medical CorporationRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Adjuvant dexamethasone
Placebo
Arm Description
Drug: Dexamethasone
Drug: Placebo
Outcomes
Primary Outcome Measures
Renal scarring comparatively with patients those don't take the medicine
Division of Children With Renal Scarring at the Outcome of (DMSA) Renal Scan [ Time Frame: The outcome DMSA scan will be 6 months from enrollment.] Renal scarring is defined as decreased uptake of tracer with or without loss of contours.
Three radiologists independently will review all renal DMSA scans for scarring .
Diagnosis of presence or absence of renal scarring for a kidney , should be endorsed by the majority of readers (2/3).
The child will be determined to have renal scarring if either kidney or both kidneys have scarring by the majority of readers.
Secondary Outcome Measures
Full Information
NCT ID
NCT04654507
First Posted
November 30, 2020
Last Updated
July 24, 2023
Sponsor
Hamad Medical Corporation
1. Study Identification
Unique Protocol Identification Number
NCT04654507
Brief Title
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
Official Title
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children:A Multi-centre, Double-blind, Randomized, Placebo-controlled, Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 3, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hamad Medical Corporation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Urinary tract infection (UTI) is the most frequently occurring serious bacterial infection in young children and accounts 5 to 14% of emergency department visits Formation of renal scarring in children has been associated with serious complications as hypertension, preeclampsia, and end stage renal failure in young age . So, this study aims to determine whether dexamethasone reduces the renal scarring in children will be treated with antibiotics for acute pyelonephritis.
investigators propose to conduct a multi center, randomized, placebo-controlled, double-blind clinical trial, that will evaluate the efficacy of dexamethasone (0.3 mg/kg every 12 hours per day orally for 3 days) in preventing renal scarring in young febrile children (2 months to 14 years) with a first-diagnosed UTI. 120 Participants will be enrolled over a 3-year period from 6 sites.
Detailed Description
Urinary tract infection (UTI) is the most frequently occurring serious bacterial infection in young children and accounts for 5 to 14% of emergency department visits. UTIs can be divided into asymptomatic bacteriuria, cystitis, and acute pyelonephritis (APN ). The APN is associated with an increased risk of renal damage, acquired through renal scarring. Which is a consequence of the inflammatory and immune response that aim to eradicate the bacteria involved in the UTI.
Parenchymal infection can be solved, but there are a number of poorly understood factors that may perpetuate inflammation, and this would promote the formation of scarring. One of the most relevant factors involved in formation of renal scarring is the production of inflammatory mediators (complement proteins, bactericidal peptides, cytokines , chemokines, ). hence, the use of anti-inflammatory drugs may prevent the release of these mediators and the formation of permanent renal scarring. Renal scarring in childhood has been associated with serious complications as hypertension, preeclampsia, and ESRD in young age.
Current treatment of children with UTI has focused on the treatment of vesicoureteral reflux (VUR) and on the early treatment of UTI with antibiotics. Although the presence of VUR increases the likelihood of bacteria gaining access to the kidney, correction of VUR is not sufficient to prevent scarring. Renal scarring frequently occurs in children who do not have VUR, and early diagnosis and treatment of children with VUR is not associated with a reduction in the incidence of end-stage renal disease. Similarly, early antibiotic therapy is necessary, but it is not sufficient to prevent renal scarring in most children with UTI. Because signs of UTI in children are relatively non-specific, the diagnosis is often delayed. data from many studies have shown that once the infection has localized to the renal parenchyma, treatment with antibiotics alone does not prevent scarring. hence ,It is clear that the current management is not always effective in preventing renal scarring. The proposed study aims to determine whether dexamethasone therapy - which focuses on modulation of the host inflammatory response - is effective in reducing renal scarring.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring, Acute Pyelonephritis, Hypertension in Children, Chronic Renal Failure, UTI
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Adjuvant dexamethasone
Arm Type
Active Comparator
Arm Description
Drug: Dexamethasone
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Drug: Placebo
Intervention Type
Drug
Intervention Name(s)
Dexamethasone Oral
Other Intervention Name(s)
corticosteroids
Intervention Description
Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Renal scarring comparatively with patients those don't take the medicine
Description
Division of Children With Renal Scarring at the Outcome of (DMSA) Renal Scan [ Time Frame: The outcome DMSA scan will be 6 months from enrollment.] Renal scarring is defined as decreased uptake of tracer with or without loss of contours.
Three radiologists independently will review all renal DMSA scans for scarring .
Diagnosis of presence or absence of renal scarring for a kidney , should be endorsed by the majority of readers (2/3).
The child will be determined to have renal scarring if either kidney or both kidneys have scarring by the majority of readers.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Months
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
First episode of acute febrile UTI.
From 2 months to 14 years of age.
Fever: ≥ 38.3°C, measured at home or at Pediatric Emergency centers.,
Exclusion Criteria:
Previous history of UTI.
Urinary tract abnormalities except VUR.
Antibiotic use within 7 days of enrollment (except last 48 hours)
previous renal scarring
patients included in the study and suffered second pyelonephritis during the first 6 months
Patients allergic to dexamethasone.
Endocrinology diseases.
cancer.
Planned admission to ICU
Other bacterial infection as meningitis or pneumonia
Congenital/acquired immunodeficiency
Systemic use of corticosteroids or other immunomodulation agents within 14 days of enrollment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mahmoud Alhandi Omar Helal
Phone
50074001
Email
dr.mahmoud.helal@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mahmoud Alhandi Omar Helal
Organizational Affiliation
Hamad Medical Corporation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hamad Medical Corporation
City
Doha
ZIP/Postal Code
3050
Country
Qatar
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mahmoud Alhandi Omar Helal
Phone
50074001
Email
dr.mahmoud.helal@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
We'll reach out to this number within 24 hrs